David D Chang is President and CEO of Allogene Therapeutics, Inc.. Currently has a direct ownership of 4.81 Million shares of ALLO, which is worth approximately $10.5 Million. The most recent transaction as insider was on May 16, 2024, when has been sold 344,828 shares (Common Stock) at a price of $2.9 per share, resulting in proceeds of $1,000,001. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.81M
0% 3M change
14.69% 12M change
Total Value Held $10.5 Million

David D Chang Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 16 2024
BUY
Grant, award, or other acquisition
$1,000,001 $2.9 p/Share
344,828 Added 6.69%
4,810,106 Common Stock
Mar 14 2024
SELL
Payment of exercise price or tax liability
$231,191 $4.33 p/Share
53,393 Reduced 1.18%
4,465,278 Common Stock
Jan 25 2024
BUY
Grant, award, or other acquisition
-
317,800 Added 6.58%
4,513,203 Common Stock
Mar 22 2023
BUY
Grant, award, or other acquisition
-
1,924,464 Added 31.45%
4,193,911 Common Stock
Mar 14 2023
SELL
Payment of exercise price or tax liability
$124,210 $5.56 p/Share
22,340 Reduced 0.97%
2,269,447 Common Stock
Mar 15 2022
SELL
Open market or private sale
$180,907 $7.65 p/Share
23,648 Reduced 1.02%
2,289,652 Common Stock
May 24 2021
BUY
Exercise of conversion of derivative security
$499,410 $18.22 p/Share
27,410 Added 1.17%
2,312,279 Common Stock
Mar 26 2021
BUY
Grant, award, or other acquisition
-
80,452 Added 3.4%
2,284,869 Common Stock
Mar 15 2021
SELL
Open market or private sale
$791,186 $38.57 p/Share
20,513 Reduced 0.92%
2,204,417 Common Stock
DDC

David D Chang

President and CEO
South San Francisco, CA

Track Institutional and Insider Activities on ALLO

Follow Allogene Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALLO shares.

Notify only if

Insider Trading

Get notified when an Allogene Therapeutics, Inc. insider buys or sells ALLO shares.

Notify only if

News

Receive news related to Allogene Therapeutics, Inc.

Track Activities on ALLO